An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight?s Board of Directors through a special committee thereof (the ?Special Committee?) will carefully evaluate Fall Line?s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the ?Offer?) to acquire all of the outstanding shares of common stock of the Company (the ?Company Common Stock?), other than certain excluded shares, for $0.30 per share (the ?Offer Price?), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company?s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the ?Private Company?) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the ?Note Purchase Agreement?), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the ?Private Company Notes?) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the ?Advance Notes?) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day ?go-shop? period beginning on the date of the Merger Agreement. There can be no assurances that the ?go-shop? will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required.

The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder?s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line?s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the ?Special Committee?) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee?s unanimous recommendation, the Company?s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company?s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023.

Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O?Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight.

A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.